In a retrospective study by Simmons C. et al., 20% of patients with metastatic BC underwent a change in their treatment plan based on the results of the biopsy of one metastatic lesion, and in particular, on the basis of HR and HER2 status re-assessment [115]. This evidence concerns the gene ERBB2 and breast cancer.